News & Updates

Show Multimedia Only

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026 by

Treatment with enzalutamide monotherapy demonstrates numerically higher overall survival (OS) in prostate cancer patients with high-risk biochemical recurrence (hrBCR) when compared with leuprolide alone, but the difference is not statistically significant, as shown by the results of the EMBARK study.

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026

Upadacitinib improves CD, UC in patients with prior tofacitinib failure

24 Mar 2026

Treatment with upadacitinib induces clinical remission and endoscopic improvement in most patients with severe, refractory Crohn’s disease (CD) or ulcerative colitis (UC) with prior tofacitinib failure, regardless of previous response to tofacitinib, a study has shown.

Upadacitinib improves CD, UC in patients with prior tofacitinib failure

24 Mar 2026

TXA POISEd for use in urologic surgery

24 Mar 2026 by

The POISE-3 trial supports the use of tranexamic acid (TXA) in patients undergoing urologic surgery at increased risk of bleeding.

TXA POISEd for use in urologic surgery

24 Mar 2026

Acid suppressant use tied to risk of ischaemic events in stroke patients on clopidogrel

24 Mar 2026

Acid suppressants such as potassium-competitive acid blockers (P-CABs) and proton pump inhibitors (PPIs), when used concomitantly with clopidogrel, carry an increased risk of ischaemic events in stroke patients, according to a retrospective cohort study.

Acid suppressant use tied to risk of ischaemic events in stroke patients on clopidogrel

24 Mar 2026

Less is more in relieving musculoskeletal pain in children

23 Mar 2026 by

In children with acute nonoperative musculoskeletal injury, treatment with ibuprofen alone appears adequate for relieving pain, with the addition of acetaminophen or hydromorphone yielding no additional analgesic effect, as shown in two No OUCH randomized clinical trials.

Less is more in relieving musculoskeletal pain in children

23 Mar 2026

Toxicology service a valuable resource in managing poisoning cases in SG: study

23 Mar 2026 by

Poisoned individuals form a substantial part of the patient population in Singapore, with prognoses that require early recognition and appropriate measures, according to a study.

Toxicology service a valuable resource in managing poisoning cases in SG: study

23 Mar 2026

IPF drug extends benefit in post-COVID-19 lung injuries

23 Mar 2026 by

A meta-analysis has shown the efficacy of the antifibrotic agent pirfenidone in preventing the onset and/or progression of interstitial lung abnormalities (ILAs) caused by COVID-19.

IPF drug extends benefit in post-COVID-19 lung injuries

23 Mar 2026

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Premenopausal breast cancer patients who are receiving tamoxifen as adjuvant hormone therapy appear to be at increased risk of uterine diseases, including endometrial cancer, according to a target trial emulation study from Taiwan.

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Novel antisense oligonucleotide shows disease-modifying potential in Dravet syndrome

21 Mar 2026 by

In children with Dravet syndrome, treatment with the investigational antisense oligonucleotide zorevunersen appears safe and efficacious, with seizure frequency reductions of up to 90 percent and improvements in nonseizure symptoms, according to two phase 1–2a studies (MONARCH and ADMIRAL) and the corresponding open-label extension studies (SWALLOWTAIL and LONGWING).

Novel antisense oligonucleotide shows disease-modifying potential in Dravet syndrome

21 Mar 2026

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026 by

The investigational combination of doravirine plus islatravir (DOR/ISL)—a fixed-dose, once-daily oral antiretroviral therapy (ART) regimen that does not rely on integrase strand-transfer inhibitors (INSTIs)—is shaping up to be a promising alternative in the management of HIV, showing noninferiority to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in individuals initiating treatment for the first time and maintaining virologic suppression in those switching from various ART regimens, as shown in three phase III studies presented at CROI 2026.

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Enzalutamide improves outcomes in prostate cancer with hrBCR

Enzalutamide improves outcomes in prostate cancer with hrBCR

Upadacitinib improves CD, UC in patients with prior tofacitinib failure

Upadacitinib improves CD, UC in patients with prior tofacitinib failure

TXA POISEd for use in urologic surgery

TXA POISEd for use in urologic surgery

Acid suppressant use tied to risk of ischaemic events in stroke patients on clopidogrel

Acid suppressant use tied to risk of ischaemic events in stroke patients on clopidogrel

Less is more in relieving musculoskeletal pain in children

Less is more in relieving musculoskeletal pain in children

Toxicology service a valuable resource in managing poisoning cases in SG: study

Toxicology service a valuable resource in managing poisoning cases in SG: study

IPF drug extends benefit in post-COVID-19 lung injuries

IPF drug extends benefit in post-COVID-19 lung injuries

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Novel antisense oligonucleotide shows disease-modifying potential in Dravet syndrome

Novel antisense oligonucleotide shows disease-modifying potential in Dravet syndrome

Non-INSTI-based ART combination on the horizon for broad HIV population

Non-INSTI-based ART combination on the horizon for broad HIV population